News & Analysis on Clinical Trial Services & Contract Research And Development
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
INFOGRAPHIC
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
CRO Quintiles has signed a five-year agreement to use OmniComm Systems' technology for Phase I clinic automation.
Hospira has announced US recalls for seven lots of its propofol injection and one lot of 1% Lidocaine HCI Injection due to a glass contamination.